AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04057144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance and commitment therapy (ACT) sessions, lead by 2 qualified therapists, using a manual based on Steven Hayes et al 1999 that was adapted to group therapy and includes all the dynamic processes of ACT.
Study NCT04057144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness exercises and audio recordings
Description: mindfulness exercises introduced in the ACT sessions. In addition daily home meditation exercises based on the program developed by Kabat-Zinn 2005 and with help of audio recordings.
Study NCT04057144 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program
Description: Self-management education program. Information given by a qualified health professional on pain and symptom management, stress, sleep, eating habits, mental health problems. Group discussions about thoughts and experiences.~communication skills and physical activity
Study NCT02798666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity exercise training
Description: Exercise training using sprint interval exercise
Study NCT02798666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous exercise training
Description: Exercise training using continuous exercise at constant heart rate
Study NCT04076696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scatter corrected s-DCT
Description: All patients will have a breath held s-DCT scan in an anterior-posterior direction
Study NCT04531176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Management Program (WMP)
Description: Weight Management Program (WMP)
Study NCT04531176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional care
Description: Traditional care
Study NCT04531176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine / Topiramate Extended Release Oral Capsule
Description: Medication for chronic weight management (Rx)
Study NCT04531176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone/bupropion extended-release
Description: Medication for chronic weight management (Rx)
Study NCT04531176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg
Description: Medication for chronic weight management (Rx)
Study NCT04027192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1 mg per day, orally
Study NCT04531176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Medication for chronic weight management (Rx)
Study NCT04271631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application-Based Diabetes Education
Description: Additional education was given using application, subjects were asked to open the application at least once a day
Study NCT04271631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Health coaching was given as face to face with a coach
Study NCT05198011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D customized Titanium Mesh (Study)
Description: approach for planning and augmenting atrophic posterior mandibular ridge using a pre-customized TiMe on a 3D model. The 3D surgical model will be virtually created from a cone-beam computed tomography (CBCT) and printed using Fused deposition modeling (FDM) machine. The 3D model will be then used to contour the TiMe in accordance with the needed amount of augmentation then will be used to help pack and contour the graft material.
Study NCT05198011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ridge augmentation (Control)
Description: the conventional technique of ridge augmentation using Titanium Mesh
Study NCT03773978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study NCT03773978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT02916212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized alarm profiles
Study NCT02718898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT02718898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC
Study NCT02718898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study NCT02718898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02677493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG Quadrivalent Influenza Vaccine
Description: A single 0.5mL dose administrated as an intramuscular injection.
Study NCT02677493 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-YANG Flu Vaccine Prefilled Syringe
Description: A single 0.5mL dose administrated as an intramuscular injection.
Study NCT02677493 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-YANG Trivalent Influenza Vaccine
Description: A single 0.5mL dose administrated as an intramuscular injection.
Study NCT00611936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00611936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 20mg maximum of d-amphetamine
Study NCT01796145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibroscan
Study NCT01650506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.
Study NCT01650506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib dosing will start and remain at 150 mg daily.
Study NCT02884869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubating Laryngeal Mask
Description: Direct laryngoscopy
Study NCT02884869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask
Description: Direct laryngoscopy
Study NCT02706756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
Study NCT02706756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Prescriptive exercise program of self-mobilization and/or strengthening program to address impairments of the subject.
Study NCT02706756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and advice
Description: All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
Study NCT02706756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and advice
Description: All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
Study NCT02706756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education and advice
Description: All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
Study NCT02706756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supervised neglect
Description: Monitoring of group without formal intervention.
Study NCT00641771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium (+) cholecalciferol
Description: MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
Study NCT00641771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
Study NCT03449017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cig use
Description: Self-administration of e-cig (10 puffs in 5 minutes) prior to lab task, self-administration of e-cig (10 puffs in 5 minutes) prior to ad lib alcohol, and ad lib e-cig use throughout ad lib alcohol paradigm.
Study NCT00988494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-105 ophthalmic solution
Description: Topical ocular application
Study NCT00988494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Description: Topical ocular application
Study NCT02543684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ready to eat mixed meal 1
Description: wild greens pie providing 50g of carbohydrates
Study NCT02543684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ready to eat mixed meal 2
Description: chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
Study NCT02543684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ready to eat mixed meal 3
Description: vegetable moussaka providing 50g of carbohydrates
Study NCT02543684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose load
Description: glucose load providing 50g of carbohydrates
Study NCT01345773 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric surgery
Description: Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
Study NCT04487366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reaching targeted area on the phantom model
Description: resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution
Study NCT01052493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP 1420
Description: Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.
Study NCT01052493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study NCT03793244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: TARGET protocol EN 1.5 kcal/mL
Description: Enteral nutrition
Study NCT04308122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Orthosis (CO)
Description: Immediately following surgery patients in the CO group will be fitted with a Philadelphia collar prior to being transferred to the recovery room. On the patient ward a physiotherapist will fit the patient with a Cervimax/Aspen/Miami J collar which will be worn at all times for 6 weeks according the standard of care.
Study NCT04308122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Orthosis
Description: The NO group will have no specific precautions applied to their neck range of motion.
Study NCT01750203 — intervention group
Intervention type: OTHER
Intervention: Swabs
Description: There is no intervention only swabs are being used to collect wound fluid samples
Study NCT04326517 — intervention group
Intervention type: PROCEDURE
Intervention: Nephrectomy
Description: Different therapeutic options are described in literature for emphysematous pyelonephritis. In our center, medical treatment (no invasive procedure), ureteral stent (endourologic procedure), percutaneous drainage (minimally invasive procedure), and nephrectomy are the therapeutic options for this disease.
Study NCT03457493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714-PET/MRI
Description: DPA-714-PET/MRI
Study NCT03457493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-year Follow-up DPA-714-PET/MRI
Description: PET/MRI scan with DPA-714
Study NCT03457493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714 Metabolite Analysis
Description: Participants will have an arterial line placed in their lower forearm immediately before DPA-714 PET/MRI. Serial blood samples will be pulled at specific time points during the dynamic PET/MRI.
Study NCT02405689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study NCT02405689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Study NCT02405689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study NCT02731469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131
Study NCT02727062 — intervention group
Intervention type: DEVICE
Intervention: OM Pain App
Description: Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.
Study NCT02727062 — intervention group
Intervention type: DEVICE
Intervention: Accelerometer
Description: Each patient will be issued an accelerometer and will be encouraged to wear it continuously during the study period (weekly during radiation therapy and four weeks following radiation therapy).
Study NCT03656510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 (high dose or low dose) orally twice daily for 7 days.
Study NCT02731469 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mircera®
Study NCT03656510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo (high volume or low volume) orally twice daily for 7 days.
Study NCT02892786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating Tumor Cells
Description: Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study~5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery~Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.~Patients will be followed every 3 months for two years.
Study NCT01092741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 400 mg P.O. twice daily (800 mg total daily dose)
Study NCT02831387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-321 Ophthalmic Solution
Description: P-321 Ophthalmic Solution 0.017%
Study NCT02831387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-321 Ophthalmic Solution placebo
Description: Placebo to match P-321 Ophthalmic Solution
Study NCT01832285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Description: 100mg/day, PO(in the mouth) each day during 6 weeks
Study NCT02731469 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aranesp®
Study NCT03733717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: Concentrate for solution~Route of administration: Intravenous
Study NCT02924428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Versa
Study NCT02924428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Versa
Study NCT01869582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscope, Fetal heart rate
Study NCT01869582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upright Resuscitator, Resuscitation
Study NCT01869582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler, Fetal heart rate
Study NCT01869582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Resuscitator, Resuscitation
Study NCT02724059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS with elastography followed by TBNA
Description: Endo bronchial ultrasound (EBUS) with elastography followed by TBNA from mediastinal lesions or lymph nodes
Study NCT03083353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isradipine
Description: Isradipine will be administered 90 minutes prior to the initiation of cue exposure.
Study NCT03083353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Exposure
Description: Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.
Study NCT03083353 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cue Exposure
Description: Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.
Study NCT02194673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trans free palm margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
Study NCT02194673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interesterified Palm based margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
Study NCT02194673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IE Soybean oil-based margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
Study NCT00901654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE527 vaccine
Description: First cohort: Two doses, each of 3x10\^9 cfu of each strain (9x10\^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).~Second cohort: Two doses, each of 3x10\^10 cfu of each strain (9x10\^10 cfu total per dose) administered on Days 0 and Day 21
Study NCT00901654 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
Study NCT00269360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic + Supervised Rehabilitative Exercise
Description: Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.~Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
Study NCT00269360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised Rehabilitative Exercise
Description: Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
Study NCT00269360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care education
Description: Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
Study NCT00090129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onercept
Description: Onercept will be administered subcutaneously three times a week at a dose of 150 mg, for 12 weeks of first treatment (FT) period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment or until relapse, whichever occurs first. Subjects then will be reassigned to either Onercept (150 mg) or placebo, subcutaneously three times a week, for 16 weeks. Subjects not showing 75 percent improvement in PASI score at Week 12 will receive only Onercept (150 mg) subcutaneously three times a week, for 40 weeks as open-label treatment.
Study NCT00090129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.